+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cancer Therapeutics & Supportive Care Drugs Market Research Report by Drug Class, Cancer Type, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 4829816
  • Report
  • April 2022
  • Region: Global
  • 185 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • Acacia Pharma Group Plc
  • Amgen Inc.
  • Aphios Corporation
  • Baxter International Inc.
  • Fagron Group B.V.
  • Helsinn Healthcare SA
The Global Cancer Therapeutics & Supportive Care Drugs Market size was estimated at USD 248.63 billion in 2021, USD 274.16 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.44% to reach USD 451.27 billion by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Cancer Therapeutics & Supportive Care Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Class, the market was studied across Antiemetics, Bisphosphonates, Erythropoietin-Stimulating Agents, Granulocyte-Colony Stimulating Factors, Nonsteroidal Anti-Inflammatory Drugs, and Opioids.
  • Based on Cancer Type, the market was studied across Breast Cancer, Lung Cancer, Melanoma, and Prostate Cancer.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Cancer Therapeutics & Supportive Care Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer Therapeutics & Supportive Care Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Therapeutics & Supportive Care Drugs Market, including Acacia Pharma Group Plc, Amgen Inc., Aphios Corporation, APR Applied Pharma Research s.a., Baxter International Inc., Fagron Group B.V., Helsinn Healthcare SA, Heron Therapeutics, Inc., Johnson & Johnson, Kyowa Hakko Kirin Co., Ltd., Merck & Co., Novartis International AG (Sandoz), Roche Holding AG, Tesaro,Inc, and Teva Pharmaceutical Industries Ltd..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Cancer Therapeutics & Supportive Care Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Therapeutics & Supportive Care Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Therapeutics & Supportive Care Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Cancer Therapeutics & Supportive Care Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Cancer Therapeutics & Supportive Care Drugs Market?
6. What is the market share of the leading vendors in the Global Cancer Therapeutics & Supportive Care Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Cancer Therapeutics & Supportive Care Drugs Market?
Frequently Asked Questions about the Global Cancer Therapeutics & Supportive Care Drugs Market

What is the estimated value of the Global Cancer Therapeutics & Supportive Care Drugs Market?

The Global Cancer Therapeutics & Supportive Care Drugs Market was estimated to be valued at $248.6 Billion in 2021.

What is the growth rate of the Global Cancer Therapeutics & Supportive Care Drugs Market?

The growth rate of the Global Cancer Therapeutics & Supportive Care Drugs Market is 10.4%, with an estimated value of $451.3 Billion by 2027.

What is the forecasted size of the Global Cancer Therapeutics & Supportive Care Drugs Market?

The Global Cancer Therapeutics & Supportive Care Drugs Market is estimated to be worth $451.3 Billion by 2027.

Who are the key companies in the Global Cancer Therapeutics & Supportive Care Drugs Market?

Key companies in the Global Cancer Therapeutics & Supportive Care Drugs Market include Acacia Pharma Group Plc, Amgen Inc., Aphios Corporation, APR Applied Pharma Research s.a., Baxter International Inc., Fagron Group B.V., Helsinn Healthcare SA, Heron Therapeutics, Inc. and Kyowa Hakko Kirin Co., Ltd..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Acacia Pharma Group Plc
  • Amgen Inc.
  • Aphios Corporation
  • Baxter International Inc.
  • Fagron Group B.V.
  • Helsinn Healthcare SA

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancerous patients
5.1.1.2. Innovations in the development of new drugs and therapies
5.1.1.3. Growing demand for non-invasive therapies
5.1.2. Restraints
5.1.2.1. High cost of cancer drugs
5.1.3. Opportunities
5.1.3.1. Ongoing innovations for the treatment of cancer
5.1.3.2. Clinical trials and developments of biosimilars and biologics
5.1.4. Challenges
5.1.4.1. Limited reimbursement options
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Cancer Therapeutics & Supportive Care Drugs Market, by Drug Class
6.1. Introduction
6.2. Antiemetics
6.3. Bisphosphonates
6.4. Erythropoietin-Stimulating Agents
6.5. Granulocyte-Colony Stimulating Factors
6.6. Nonsteroidal Anti-Inflammatory Drugs
6.7. Opioids
7. Cancer Therapeutics & Supportive Care Drugs Market, by Cancer Type
7.1. Introduction
7.2. Breast Cancer
7.3. Lung Cancer
7.4. Melanoma
7.5. Prostate Cancer
8. Americas Cancer Therapeutics & Supportive Care Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Cancer Therapeutics & Supportive Care Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
10. Europe, Middle East & Africa Cancer Therapeutics & Supportive Care Drugs Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Acacia Pharma Group Plc
12.2. Amgen Inc.
12.3. Aphios Corporation
12.4. APR Applied Pharma Research s.a.
12.5. Baxter International Inc.
12.6. Fagron Group B.V.
12.7. Helsinn Healthcare SA
12.8. Heron Therapeutics, Inc.
12.9. Johnson & Johnson
12.10. Kyowa Hakko Kirin Co., Ltd.
12.11. Merck & Co.
12.12. Novartis International AG (Sandoz)
12.13. Roche Holding AG
12.14. Tesaro,Inc
12.15. Teva Pharmaceutical Industries Ltd.
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET: DYNAMICS
FIGURE 2. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (%)
FIGURE 3. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (USD BILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2027
FIGURE 5. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2019-2027 (USD BILLION)
FIGURE 6. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 7. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2019-2027 (USD BILLION)
FIGURE 8. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 9. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIETIN-STIMULATING AGENTS, 2019-2027 (USD BILLION)
FIGURE 10. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIETIN-STIMULATING AGENTS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 11. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, 2019-2027 (USD BILLION)
FIGURE 12. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 13. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2019-2027 (USD BILLION)
FIGURE 14. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 15. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2019-2027 (USD BILLION)
FIGURE 16. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 17. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2021 VS 2027 (%)
FIGURE 18. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2021 VS 2027 (USD BILLION)
FIGURE 19. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2027
FIGURE 20. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, 2019-2027 (USD BILLION)
FIGURE 21. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 22. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, 2019-2027 (USD BILLION)
FIGURE 23. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 24. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MELANOMA, 2019-2027 (USD BILLION)
FIGURE 25. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 26. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, 2019-2027 (USD BILLION)
FIGURE 27. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 28. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 29. ARGENTINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 30. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 31. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 32. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 33. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 34. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 35. AUSTRALIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 36. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 37. INDIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 38. INDONESIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 39. JAPAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 40. MALAYSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 41. PHILIPPINES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 42. SINGAPORE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 43. SOUTH KOREA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 44. TAIWAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 45. THAILAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 46. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 47. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 48. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 49. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 50. NETHERLANDS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 51. QATAR CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 52. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 53. SAUDI ARABIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 54. SOUTH AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 55. SPAIN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 56. UNITED ARAB EMIRATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 57. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 58. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 59. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 60. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD BILLION)
TABLE 4. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2019-2027 (USD BILLION)
TABLE 5. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 6. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY STATE, 2019-2027 (USD BILLION)
TABLE 7. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 9. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2019-2027 (USD BILLION)
TABLE 10. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 11. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY STATE, 2019-2027 (USD BILLION)
TABLE 12. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 14. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIETIN-STIMULATING AGENTS, BY REGION, 2019-2027 (USD BILLION)
TABLE 15. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIETIN-STIMULATING AGENTS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 16. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIETIN-STIMULATING AGENTS, BY STATE, 2019-2027 (USD BILLION)
TABLE 17. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIETIN-STIMULATING AGENTS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIETIN-STIMULATING AGENTS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 19. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, BY REGION, 2019-2027 (USD BILLION)
TABLE 20. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 21. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, BY STATE, 2019-2027 (USD BILLION)
TABLE 22. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 23. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 24. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2019-2027 (USD BILLION)
TABLE 25. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 26. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY STATE, 2019-2027 (USD BILLION)
TABLE 27. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 28. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 29. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2019-2027 (USD BILLION)
TABLE 30. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 31. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY STATE, 2019-2027 (USD BILLION)
TABLE 32. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 33. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 34. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2019-2027 (USD BILLION)
TABLE 35. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 36. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 37. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 38. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 39. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 40. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 41. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 42. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 43. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 44. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 45. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2019-2027 (USD BILLION)
TABLE 46. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 47. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MELANOMA, BY STATE, 2019-2027 (USD BILLION)
TABLE 48. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 50. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 51. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 52. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 53. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 55. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 56. ARGENTINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 57. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 58. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 59. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 60. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 61. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 62. AUSTRALIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 63. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 64. INDIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 65. INDONESIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 66. JAPAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 67. MALAYSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 68. PHILIPPINES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 69. SINGAPORE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 70. SOUTH KOREA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 71. TAIWAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 72. THAILAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 74. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 75. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 76. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 77. NETHERLANDS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 78. QATAR CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 79. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 80. SAUDI ARABIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 81. SOUTH AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 82. SPAIN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 83. UNITED ARAB EMIRATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 84. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 85. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET: SCORES
TABLE 86. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET: BUSINESS STRATEGY
TABLE 87. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET: PRODUCT SATISFACTION
TABLE 88. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET: RANKING
TABLE 89. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 90. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET: MERGER & ACQUISITION
TABLE 91. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 92. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 93. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET: INVESTMENT & FUNDING
TABLE 94. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 95. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Acacia Pharma Group Plc
  • Amgen Inc.
  • Aphios Corporation
  • APR Applied Pharma Research s.a.
  • Baxter International Inc.
  • Fagron Group B.V.
  • Helsinn Healthcare SA
  • Heron Therapeutics, Inc.
  • Johnson & Johnson
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Co.
  • Novartis International AG (Sandoz)
  • Roche Holding AG
  • Tesaro,Inc
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown

Loading
LOADING...